Levodopa: The Gold Standard in the Treatment of Parkinson's Disease

Supported through an educational grant from F. Hoffman-LaRoche, Ltd.

The content of this Enduring Educational Activity was derived from The Movement Disorder Society's 10th International Congress of Parkinson's Disease and Movement Disorders.

Accreditation Statement
The Movement Disorder Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Movement Disorder Society designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Target Audience
This activity has been designed to meet the educational needs of Movement Disorder specialists, general neurologists, physicians-in-training, and other healthcare professionals interested in the current research and approaches for the diagnosis and treatment of Parkinson's disease.

Learning Objectives
At the conclusion of the activity, participants should be able to:

1. Know the pros and cons of initiating therapy early with levodopa;
2. Describe the late complications of levodopa therapy and their mechanisms of causation;
3. Know which symptoms of Parkinson's disease are dopa responsive and which require alternative therapeutic approaches.

Faculty List with Degrees and Affiliations

Chairs:
Andrew J. Lees, MD, FRCP
London, United Kingdom

Niphon Poungvarin, MD, FRCP
Bangkok, Thailand

Faculty:
Stanley Fahn, MD
New York, New York USA

Eduardo Tolosa, MD
Barcelona, Spain